MAPT and Alzheimer disease: Recently, blood tests based on tau phosphorylated at threonine 217 (phosphorylated-tau217) have been shown to detect AD pathology with accuracies of around 90% in both primary and secondary care6, demonstrating performances comparable to clinically used CSF tests10.